RO INTEGRATES WITH NOVOCARE® PHARMACY TO PROVIDE SEAMLESS ACCESS TO WEGOVY® AT THE LOWEST CASH PRICE
NEW YORK, April 29, 2025 /PRNewswire/ -- Ro today announced an integration with NovoCare® Pharmacy to provide seamless access to all doses of Wegovy® at the best available cash price of $499 per month. By working directly with Novo Nordisk's direct-to-patient option NovoCare® Pharmacy, Ro ensures patients have a reliable supply of FDA-approved GLP-1 medication directly from the manufacturer. With Ro's streamlined experience, patients can consult with a provider and get access to effective GLP-1 medication at the lowest cash price, without ever having to leave the Ro app.
'Fighting for patients means making it as easy and affordable as possible to access high-quality treatment, and that's exactly what integrating with NovoCare® Pharmacy offers patients,' said Zach Reitano, co-founder and CEO of Ro. 'Adding Novo Nordisk's FDA-approved treatments at the best available cash price will help more patients nationwide get the obesity care they need to achieve their goals, particularly those without insurance coverage.'
Ro makes it easy for patients to achieve their health goals by vertically integrating telehealth, lab and pharmacy services all onto one platform. With the Body Membership, patients have access to high-quality, obesity care including: access to a licensed physician, 24/7 messaging, 1-1 coaching, educational content, weight tracking and dose logging, labs, side-effect monitoring, and monthly check-ins to handle everything from dose titration to counseling.
This integration adds to Ro's obesity care formulary, already one the most comprehensive of any telehealth company, integrating cash pay and insurance eligible options that can be picked up at a retail pharmacy or delivered. With the Ro Insurance Checker, anyone can verify their benefits coverage for free and find the best possible medication choice at the lowest possible price – whether that's using insurance coverage or paying cash. To date, Ro has helped hundreds of thousands of people understand their benefits coverage to get the best medication for them.
Since its founding, Ro has invested in its direct-to-patient model designed to give patients nationwide more affordable, easier access to high-quality care. By integrating with NovoCare® Pharmacy, Ro is scaling high-quality care for the most common chronic condition in the U.S. at a fraction of the cost. CenterWell Pharmacy is the dispensing pharmacy managing prescription fulfilment and delivery for NovoCare® Pharmacy.
About Ro
Ro is a direct-to-patient healthcare company with a mission of helping patients achieve their health goals by delivering the easiest, most effective care possible. Ro is the only company to offer nationwide telehealth, labs, and pharmacy services. This is enabled by Ro's vertically integrated platform that helps patients achieve their goals through a convenient, end-to-end healthcare experience spanning from diagnosis, to delivery of medication, to ongoing care. Since 2017, Ro has helped millions of patients, including one in every county in the United States, and in 98% of primary care deserts.
Contact: [email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/ro-integrates-with-novocare-pharmacy-to-provide-seamless-access-to-wegovy-at-the-lowest-cash-price-302441159.html
SOURCE Ro
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
My doctor shamed me when I asked about weight loss drugs. But they've helped me lose 80 pounds and stop binge eating.
"Yay science." For years, Elyse Schroeder had a secret routine. She would wake up with constant thoughts of food playing on loop in her mind. Schroeder would deny her cravings, delaying her first bites as long as she could in an effort to limit her daily calorie intake. But once she was alone, the binging would begin. 'The second my kids would go to school, I would be eating,' she tells Yahoo. 'I would go get fast food and hide the evidence at the bottom of the garbage — there was this cycle of shame that I couldn't get control of.' But not for lack of trying. Schroeder says she tried 'every fad diet that exists.' She joined gyms and worked with dietitians. It would work, for a while, and she would lose some weight. Ultimately, however, 'I couldn't get over the obsession with food, and eventually I would undo every good choice I had made,' she says. 'I couldn't get control of my disordered eating.' She was desperate not to pass her toxic relationship with food onto her children, and knew that diets weren't the solution. Then, the 39-year-old content creator and social media marketing specialist saw people talking about GLP-1 weight loss medications on TikTok. After finding out she was prediabetic, Schroeder asked her doctor about the drugs. 'Her verbatim words were 'I don't believe in those medications, and I really think we can help you with diet and exercise'' — the same ineffective methods Schroeder had tried for years. 'She didn't help me, she shamed me,' says Schroeder. So she struck out on her own to get compounded tirzepatide. Over the course of two years on the medication, Schroeder has lost more than 80 pounds and restored her relationship with food. When she met with a new doctor, 'The first thing she said to me was, 'I hope you are so proud of yourself,'' says Schroeder. 'I burst into tears.' And she is proud of herself, not because of the weight loss but because 'I feel so at peace with my life and where I am in my relationship with food,' she says. For this edition of Yahoo's On My Weigh series, Schroeder shares in her own words all the positive changes 'one little weekly injection has brought' to her life: 'Yay science!' The Weigh-in Name: Elyse Schroeder Age: 39 The method: Compounded tirzepatide, 12.5 milligrams The goal: Before I started tirzepatide, I had bloodwork done, and my doctor told me I was prediabetic. So when I decided to try the medication, truly my only goal was to get my bloodwork back to normal. I didn't care about losing weight, though I hoped I might. As a mom of three kids, I didn't want to die early or to pass on my disordered eating to them. I was 220 pounds when I took my first dose of tirzepatide, and I was just trying to get under 190 pounds. That's not even a healthy body mass index (BMI) for me, but I didn't think I'd be able to lose more than that. Progress report card: I couldn't even tell you the last time I've had an episode of binge eating. It's definitely been at least a year. I eat when it's time to eat, not to soothe myself. My blood work is passed-with-flying-colors stellar. My doctor is so happy. I go to the gym four to five times a week, happily. Once I surpassed my 190-pound goal, my new goal weight became 150 pounds. After I hit that, my doctor suggested that, because of my relationship with food, we should focus on my body fat percentage, rather than weight. My body fat has decreased, and my muscle mass has increased. I now bounce between 138 and 140 pounds, but I don't really care because I'm focused on being strong and healthy. Food noise volume: Before tirzepatide, my food noise volume was at a 10. I would be eating and thinking about what I was going to eat after that. I would force myself to go to sleep early just to stop thinking about food. It was all-consuming. And there was so much shame that went along with that: Why can't I feel full or pack up leftovers like other people? I thought it was an issue of self-control or motivation, but now that I have the medication, I realize that my brain handles food noise differently than that of a person without the disease of obesity. Now, my food noise volume is at about a 3. I basically only experience it when I'm hungry! Day in the Life Rise and shine Before taking tirzepatide, I felt like a slug. It was so hard getting my body out of bed, and I didn't feel excited for the day. I would just think, Another day of struggling, of self-loathing, of wondering why I can't fix this. My sleep and morning mood have been so affected by tirzepatide. I wake up excited and ready for the day. I love a good cup of coffee, but often I don't even really need it in the morning. I just drink it because it's yummy. And I look forward to going to the gym first thing in the morning now. If you told the old me that the gym would become one of my favorite parts of the day, I would've been like, 'You're high.' First bites I used to try to delay breakfast and starve myself in the morning, thinking I would eat fewer calories that way. But I've learned that that was dumb because then I'd get to Starbucks after my kids went to school, and my brain would be in this ravished state. I'd get their double-smoked bacon, cheddar and egg sandwich. Honestly, that sandwich still slaps, but it's just two flimsy pieces of bacon, so it's really not doing that much protein- and nutrition-wise. Despite trying so many diets, my knowledge of nutrition before tirzepatide was really not great. I thought protein came from peanut butter, the end. Now, I eat a very protein-heavy diet. I start my day with a protein shake of some sort while I'm getting the kids ready for school and before I head to the gym. When I get home, I usually make some eggs with some fruit and maybe some sausage. I'm a creature of habit and, as long as I'm not sick of eating it, having the same thing every day eliminates the stress of coming up with something new. Get ready with me Before starting tirzepatide, I truly had like five outfits. I thought there was no point in spending money on clothes when I didn't like how anything looked on me. Now, to my husband's dismay, I love getting dressed and buying new clothes. When you can fit in anything that feels exciting to you, it's fun to get dressed. I used to only wear black, but now in the morning I get to ask what colors I want to wear today — and sometimes it's bright pink. I love doing my makeup and hair now too. It feels like I love myself enough to get ready. Make a move I'm now an Orangetheory girlie, and I like to go to the 7:15 a.m. class, because if I don't do it in the morning, my body says 'no' to the gym. I love the mixture of cardio and lifting weights on the floor. I never thought I would like lifting weights, but now I'm starting to see definition, which is exciting, and I just really enjoy it. I waited until about a month before I entered my maintenance phase (and was no longer trying to lose more weight) to start going to the gym. Orangetheory is really hard, even at a healthy weight — it would have really hurt when I was carrying 80 additional pounds. And I didn't feel like I belonged there. I imagined everyone would think, Oh, there's the fat girl, trying to lose weight … what did she eat before this? Earlier on in my journey, I told myself that any movement is good movement, so I walked every day with my dog for at least 30 minutes. And then one morning — maybe because it was winter and cold in Wisconsin — I just woke up and decided to try Orangetheory. I was so scared to go to my first class, because I had no idea what to do in a gym. But the structure of Orangetheory — where someone is like, 'Here's how you hold a weight, here's how you lift it, now do it 10 times' — has been great for me. Dose time For the first six months I was taking it, I had pretty much all of the side effects of tirzepatide, except constipation and vomiting (though I tried semaglutide a year before tirzepatide, and it made me throw up so much I quit after three shots). So I had to make sure I got plenty of electrolytes and ate very clean and protein-heavy the day before I took my injection. And I started taking psyllium husk to help with diarrhea. I always try to take it in the morning, so that I have the rest of the day to recover if my tummy is a little wonky. If I try to take it in the afternoon or evening, I just wake up feeling a little hungover and uneasy the next day. Since entering the maintenance phase in March, I'm a little more flexible on my shot schedule. Sometimes I wait nine or 10 days to take it instead of a week, if I hit day 7 and don't feel like my food noise is coming back. I typically take my shot on Tuesdays. That way, when the weekend comes, if I decide to have a glass of wine, it doesn't upset my tummy. I don't really get side effects now, except that I'm cold a lot, and like some others on GLP-1s, I get a little allodynia, a kind of skin sensitivity that makes it feel like I have a mild sunburn on the backs of my arms or legs. But it's all manageable, and I've never considered quitting tirzepatide. Let's do lunch Lunch before tirzepatide was always some kind of packaged or fast food. And I would overeat at lunch, feel like crap and need a nap every single day. I'll admit: I don't love cooking. It stresses me out because I can't forward-plan. But my husband is the best. He meal preps for me so my lunch is set to go. I love the salads and wraps he makes me. My current fixation is his Mediterranean bowls with chicken, rice, hummus, olives, pita — I could eat them every day! It's crazy how much my cravings have changed. I wanted burgers and fries; now I really crave protein and fruit and veggies. I never craved stuff like that before. Happy hour Happy hours and social outings used to be such a point of stress for me when I was doing these very rigid diets, like Whole30, paleo and WeightWatchers. I wouldn't want to go to happy hour because I knew that that would be a free-for-all where I would want to over-consume food and alcohol. I can be honest about it now that I'm on the other side: I was drinking too much before I started taking tirzepatide. I really wanted to be free from all the shame and worry I felt in social settings. Now, with the medication, those things don't stress me out at all. I know that the medication will naturally moderate how much I take in. I have about a glass of wine a month. I know I'm not going to eat healthily like I do at home when I go to these events, and that's OK. I can lean into it now and have fun and know that tomorrow I'm going to go back to my routine. Before, it felt like every outing meant I was falling off the wagon and had to start over again. These days, going out feels stress-free. Plus, being on weight loss medication has opened up a whole new world of outdoor activities I do with my family. Before, my husband would take the kids for a hike on a weekend afternoon. I would stay home and take a nap. I didn't feel like I could keep up, and it didn't sound fun. Now I'm the one planning hikes. We just got back from the Badlands in South Dakota, where we were hiking and climbing for days, and it was so much fun! Before tirzepatide, that would've sounded like torture to me. It makes me sad to think about the things I chose not to participate in and how much I missed out on when my kids were little because I just didn't have the energy to do things with them. Dinner bell One of my favorite things about this process is how dinner has changed: My whole family eats at the table together. It's difficult now that the kids are at the age of after-school activities, but it's important. In the era of my crash dieting, I was always eating something different from them because I had been 'bad' during the day, so I felt like I had to undo the damage. What message was that sending to the kids, that I couldn't eat what they were eating? Now that my kids are older, it's so important for them to have a healthy relationship with food. I want them to understand that just because I'm a woman, that doesn't mean I need to only eat leaves. I don't want to put a thought in their heads that they have to diet, which is part of why, for the time being, they don't know that I'm taking weight loss medications. Now, we all eat the same thing. Often, that's something nutritious that my husband cooked on the grill. My daughter loves to make salad; she calls it 'her specialty.' So we'll have a salad she made, some vegetables and some kind of carb. And sometimes we have a frozen pizza — and that's OK. Let's get the bill I'm telling you, if I had to get a second job to make enough money to pay for this medication, I would do it in a heartbeat. I pay for a $79-a-month membership to my telehealth provider, and it's $99 for a month's supply of tirzepatide, no matter what the dose. When I think about how much I used to spend on groceries and drive-throughs — it was just so much food — it was insane. My husband and I laugh now because we'll put together an Instacart order and he'll be like, 'This total is so low!' And it's because I'm not ordering 12 bags of Doritos; that's expensive! Yes, produce and whole foods are expensive too, but I'm eating a normal amount now. So, I feel like, financially, it all comes out in the wash now. Solve the daily Crossword
Yahoo
an hour ago
- Yahoo
Antisense & RNAi Therapeutics Market Outlook 2025-2033: Advancements in Drug Delivery Propel Growth with Revenues Forecast to Reach $3.3 Billion by 2033
Antisense & RNAi Therapeutics Market Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The "Antisense & RNAi Therapeutics Market by Technology, Route of Administration, Application, and Region 2025-2033" has been added to offering. The global antisense & RNAi therapeutics market is poised for significant growth, with the market size projected to rise from USD 1.8 Billion in 2024 to USD 3.3 Billion by 2033, at a CAGR of 7.03% from 2025 to 2033. This growth is driven by a high prevalence of genetic and chronic diseases, supportive regulatory environments, and technological advancements in drug delivery systems. Antisense & RNAi Therapeutics Market Analysis: Major Market Drivers: Technological advancements in drug delivery systems and the prevalence of genetic disorders and chronic diseases. Key Market Trends: Personalized medicine and improved patient outcomes. Geographical Trends: North America leads the market due to its robust healthcare infrastructure and regulatory support. Competitive Landscape: A dynamic market featuring traditional pharmaceutical giants and innovative newcomers battling for patents and regulatory approvals. Challenges and Opportunities: High development costs present both obstacles and opportunities for innovation. Technological Advancements in Drug Delivery Technologies that improve RNA molecule delivery have become a major driver, enhancing efficacy in targeting specific cells. Lipid nanoparticles and conjugate technologies exemplify how delivery has improved, particularly for cancer and viral infections. Increasing Prevalence of Genetic Disorders The growing incidence of genetic and chronic diseases propels market growth. These therapeutics represent new treatment avenues, particularly for conditions unmanageable with conventional methods, fueling investment in biopharmaceutical R&D. Supportive Regulatory Environment Regulatory incentives, such as orphan drug status and faster review processes, are pivotal in driving market demand. For instance, the FDA's support enhances RNAi and antisense development. Market Segmentation Technology: RNA Interference, siRNA, miRNA, Antisense RNA Route of Administration: Includes intravenous, subcutaneous, and pulmonary delivery, with the latter holding the largest share due to its efficacy in respiratory treatments. Application: Oncology, cardiovascular diseases, respiratory disorders, and more. Region: North America leads, supported by its biotechnological infrastructure and the prevalence of target diseases. Competitive Landscape Key players like Alnylam Pharmaceuticals and Ionis Pharmaceuticals are increasing their R&D investments, engaging in strategic acquisitions and partnerships to harness emerging technologies. This strategy not only enhances their competitive edge but also accelerates the introduction of new RNA-based therapies to the market. Key Questions Answered in This Report: Market size and expected growth rate from 2025 to 2033? Key factors driving market growth? Impact of COVID-19 on the market? Technology and route of administration breakdowns? Leading regions and key players in the market? Key Attributes Report Attribute Details No. of Pages 135 Forecast Period 2024-2033 Estimated Market Value (USD) in 2024 $1.8 Billion Forecasted Market Value (USD) by 2033 $3.3 Billion Compound Annual Growth Rate 7% Regions Covered Global Key Topics Covered 1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Antisense & RNAi Therapeutics Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Technology 6.1 RNA Interference 6.2 Antisense RNA 7 Market Breakup by Route of Administration 7.1 Intravenous Route 7.2 Subcutaneous Route 7.3 Intrathecal Route 7.4 Pulmonary Delivery 7.5 Intraperitoneal Injection 7.6 Others 8 Market Breakup by Application 8.1 Oncology 8.2 Cardiovascular Diseases (CVDs) 8.3 Respiratory Disorders 8.4 Renal Diseases 8.5 Neurodegenerative Disorders 8.6 Genetic Disorders 8.7 Infectious Diseases 8.8 Others 9 Market Breakup by Region 9.1 North America 9.2 Asia-Pacific 9.3 Europe 9.4 Latin America 9.5 Middle East and Africa 10 SWOT Analysis 11 Value Chain Analysis 12 Porters Five Forces Analysis 13 Price Analysis 14 Competitive Landscape Companies Featured Alnylam Pharmaceuticals Inc. Arbutus Biopharma Corporation Arrowhead Pharmaceuticals Inc. Benitec Biopharma Ltd. Bio-Path Holdings Inc. Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S) Ionis Pharmaceuticals Inc. OliX Pharmaceuticals Inc. Phio Pharmaceuticals Corp. Sarepta Therapeutics Inc. Silence Therapeutics Sirnaomics Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Antisense & RNAi Therapeutics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
Exclusive-China's Sciwind is in talks to license weight-loss drug in US, CEO says
By Andrew Silver HANGZHOU (Reuters) -China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for American patients, the drugmaker's chief executive told Reuters. Overweight patients treated with Sciwind's ecnoglutide drug lost an average of 10% to 15% of their body weight, roughly in line with results from Novo Nordisk's top-selling obesity treatment Wegovy, according to a late-stage study published in medical journal The Lancet Diabetes & Endocrinology in June. 'We also hope we are able to successfully license out, and they will apply for approval in the U.S.,' Sciwind Biosciences CEO Pan Hai said, declining to identify the firm or disclose financial terms under discussion. Reuters is the first to report on the potential U.S. licensing deal. Pan said its potential partner hoped to gain U.S. marketing approval to prescribe ecnoglutide for multiple medical conditions and would carry out further clinical development. The talks are not yet at the stage of discussing a detailed contract, he added. Sciwind is hoping the partner could use clinical data accumulated in China and Australia to accelerate the development. Pan expects it would take at least three years for a U.S. partner to bring Sciwind's drug to market in the United States, and said the FDA might require a bridging study to compare ecnoglutide's pharmacokinetics - how it moves through the body - among different patient populations. Ecnoglutide is administered as a once-weekly injection. It belongs to a class of drugs called GLP-1 receptor agonists, which work by helping control blood sugar levels and triggering a feeling of fullness. Novo's Wegovy and Eli Lilly and Co's Zepbound lead the U.S. market for weight-loss drugs, but their relatively high prices leave room for new competitors to offer cheaper alternatives. Sciwind has applied to sell ecnoglutide in China for weight management and the treatment of type II diabetes. Other approved weight loss medicines in China also include drugs from Novo, Lilly and other drugmakers. Pan said he could not give an estimated time of approval. The company is also in talks to license the drug to partners for other markets, including in Latin America and the Middle East. Pricing in China would be in line with other approved competitors, Pan said, adding the company would not engage in a "price war" there. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
